INS and type 2 diabetes mellitus: In a post hoc analysis of SURPASS-1, tirzepatide monotherapy at doses 5, 10 and 15 mg was shown to induce significant improvements in several fasting biomarkers of pancreatic β-cell function and insulin sensitivity, effects which were only partially attributable to the observed weight loss, shedding more light into the underlying pathophysiological mechanisms explaining the improved glycaemic control of patients with T2D under tirzepatide treatment [54].